Automated system for on-line desorption of dried blood spots applied to LC/MS/MS pharmacokinetic study of flurbiprofen and its metabolite.

Unit of Toxicology, University Center of Legal Medicine, Geneva, Switzerland; Swiss Centre for Applied Human Toxicology, University of Geneva, Geneva, Switzerland.
Journal of pharmaceutical and biomedical analysis (Impact Factor: 2.45). 01/2011; 54(2):359-67. DOI: 10.1016/j.jpba.2010.08.032
Source: PubMed

ABSTRACT This paper illustrates the development of an automated system for the on-line bioanalysis of dried blood spots (on-line DBS). In this way, a prototype was designed for integration into a conventional LC/MS/MS, allowing the successive extraction of 30 DBS toward the analytical system without any sample pretreatment. The developed method was assessed for the DBS analysis of flurbiprofen (FLB) and its metabolite 4-hydroxyflurbiprofen (OH-FLB) in human whole blood (i.e. 5 μL). The automated procedure was fully validated based on international criteria and showed good precision, trueness, and linearity over the expected concentration range (from 10 to 1000 ng/mL and 100 to 10,000 ng/mL for OH-FLB and FLB respectively). Furthermore, the prototype showed good results in terms of recovery and carry-over. Stability of both analytes on filter paper was also investigated and the results suggested that DBS could be stored at ambient temperature for over 1 month. The on-line DBS automated system was then successfully applied to a pharmacokinetic study performed on healthy male volunteers after oral administration of a single 50-mg dose of FLB. Additionally, a comparison between finger capillary DBS and classic venous plasma concentrations was investigated. A good correlation was observed, demonstrating the complementarity of both sampling forms. The automated system described in this article represents an efficient tool for the LC/MS/MS analysis of DBS samples in many bioanalytical applications.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Dried blood spots (DBS), a micro blood sampling technique, has recently gained interest in drug discovery and development due to its inherent advantages over the conventional whole blood, plasma or serum sample collection. Since the regulatory authorities have agreed to the use of blood as an acceptable biological matrix for drug exposure measurements, its applications have been extended not only to therapeutic drug monitoring but also to toxicokinetic and pharmacokinetic studies. The pharmaceutical industry is keen to promote DBS as a prominent tool in bioanalytical applications due to the financial, ethical and organizational issues involved in clinical trials. This could be accomplished due to the latest advances in modern analytical technology, particularly liquid chromatography-mass spectrometry. The present review discusses some of the emerging liquid chromatography-mass spectrometry technologies in improving DBS analysis for its innovative applications in the development of new drugs.
    Expert Review of Proteomics 04/2014; · 3.90 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: RATIONALEFor Newborn Screening (NBS) programs all over the world whole blood dried on filter paper, also referred to as dried blood spots (DBS), has been the standard specimen for decades. In recent years DBS have attracted the attention of pharmaceutical companies, mostly due to the low volume of collected sample and simplified, therefore more cost-efficient, transportation requirements. However, the classical NBS workflow did not totally fulfil the needs of their studies, especially with respect to high-throughput unassisted sample processing for tandem mass spectrometric (MS/MS) analysis. Automated on-line extraction systems for direct analysis have already been tested and proved to be suitable for these pharmaceutical applications. METHODS The suitability of the automated CAMAG DBS-MS 500 interface for simultaneous detection of amino acids and (acyl-)carnitines has been tested together with an Acquity TQD tandem mass spectrometer from Waters and MassChrom stable isotope labelled internal standards from Chromsystems. No chromatographic sample treatment was applied; instead, the extract was directly injected into the MS/MS instrument. The feasibility of the instrumental setting for the routine newborn screening was tested on original samples coming from previously diagnosed patients. RESULTSThe performance of the automated extraction technique and its application in preliminary quantitative screening for amino acids and (acyl-)carnitines for NBS showed very promising results. Several samples from patients, each diagnosed with one of four different inborn errors of metabolism (IEM), were tested and the correlation with the conventional punch-and-elute approach was very good. CONCLUSIONS Although the presented method still needs further optimization, our study clearly shows the possibility to use direct on-line analysis in the NBS setting. Our report on direct on-line analysis of newborn samples is a first approach in the development of a fully automated screening method for NBS analysis. With regard to the chemical properties of the analytes, the study resulted in a readily applicable screening method. Copyright © 2014 John Wiley & Sons, Ltd.
    Rapid Communications in Mass Spectrometry 04/2014; 28(8). · 2.51 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Dried blood spot (DBS) sampling, a technique for whole blood sampling on a piece of filter paper, has more than 50-years tradition, particularly in the diagnostic analysis of metabolic disorders in neonatal screening. Due to the minimal invasiveness, straightforwardness, robustness against manipulation and fastness DBS sampling recommends itself as an advantageous technique in doping control analysis. The present approach highlights the development of a screening assay for the analysis of eight anabolic steroid esters (nandrolone phenylpropionate, trenbolone enanthate, testosterone acetate, testosterone cypionate, testosterone isocaproate, testosterone phenylpropionate, testosterone decanoate and testosterone undecanoate) and nandrolone in DBS. The detection of the intact esters allows an unequivocal proof of the administration of conjugates of exogenous testosterone and its derivatives. Precise, specific and linear conditions were obtained by means of liquid chromatography high resolution/high accuracy mass spectrometry. Sensitivity in the low ppb range was accomplished by the preparation of the methyloxime derivatives of the target compounds. Labeled internal standards (d3-nandrolone, d3-nandrolone caproate and d3-nandrolone undecanoate) were applied to compensate for the broad range in chain length of the esters. The assay presented here outlines the application of DBS for the analysis of anabolic steroid esters in doping controls for the first time providing great potential to simplify the proof of exogenous administration of testosterone.
    Journal of pharmaceutical and biomedical analysis 03/2014; 96C:21-30. · 2.45 Impact Factor

Full-text (3 Sources)

Available from
Jun 2, 2014